ArticleMedicine2018
Gene pair based prognostic signature for colorectal colon cancer.
Article in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A Platform-Independent Binary Gene-Pair Signature Derived from CRPC-Enriched Single-Cell Transcriptomics for Predicting Recurrence-Free Survival in Prostate Cancer.Cancer management and research · 2026Article
- Development of novel DNAJB6-KIAA1522-p-mTOR three-protein prognostic prediction models for CRC.Translational oncology · 2023Article
- Competing Endogenous RNA in Colorectal Cancer: An Analysis for Colon, Rectum, and Rectosigmoid Junction.Frontiers in oncology · 2021Article
- Development and verification of a personalized immune prognostic feature in breast cancer.Experimental biology and medicine (Maywood, N.J.) · 2020Article
- An Individualized Immune Prognostic Index is a Superior Predictor of Survival of Hepatocellular Carcinoma.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Article
- A qualitative transcriptional signature for predicting microsatellite instability status of right-sided Colon Cancer.BMC genomics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe identification of high-risk colorectal cancer (CRC) patient is key to individualized treatment after surgery and reliable prognostic biomarkers are needed identifying high-risk CRC patients.
methodsWe developed a gene pair based prognostic signature that could can the prognosis risk in patients with CRC. This study retrospectively analyzed 4 public CRC datasets, and 1123 patients with CRC were divided into a training cohort (n = 300) and 3 independent validation cohorts (n = 507, 226, and 90 patients).
resultsA signature of 9 prognosis-related gene pairs (PRGPs) consisting of 17 unique genes was constructed. Then, a PRGP index (PRGPI) was constructed and divided patients into high- and low-risk groups according to the signature score. Patients in the high-risk group showed a poorer relapse-free survival than the low-risk group in both the training cohort [hazard ratio (HR) range, 4.6, 95% confidence interval (95% CI), 2.55-8.32; P < .0001] and meta-validation set (hazard ratio range, 4.09, 95% CI, 1.99-8.39; P < .0001). The PRGPI signature achieved a higher accuracy [mean concordance index (C-index): 0.6∼0.74] than a commercialized molecular signature (mean C-index, 0.48∼0.56) for estimation of relapse-free survival in comparable validation sets.
conclusionThe gene pair based prognostic signature is a promising biomarker for estimating relapse-free survival of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.